Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00994370 · ClinicalTrials.gov registry record
Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT
A clinical trial of Liver Cancer, sponsored by Rutgers, The State University of New Jersey.
- Completed
- Registry status
- 36
- Enrollment target
- 1
- Study location
NCT00994370: Completed study of Liver Cancer, sponsored by Rutgers, The State University of New Jersey.
NCT00994370 is a study of Liver Cancer that has completed, run by Rutgers, The State University of New Jersey. The registered enrollment target is 36 participants, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00994370, a study of Liver Cancer, has completed, sponsored by Rutgers, The State University of New Jersey.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to investigate the influence of giving radiation to the liver on tumors involving the liver. Investigator is specifically looking at this effect on the blood vessels within the tumor. This effect will be measured by studying substances in the blood that the tumors produce and that cause blood vessels to grow. The effects seen on these substances may help design other treatments to improve the results of the radiation used to treat these tumors.
Primary Outcome
Primary objective is to develop assays for both cellular and peptide pro-angiogenic markers and determine variability of these makers in patients with hepatic malignancy before and after Selective Internal Radiation Therapy (SIRT).
Conditions Studied
Study Locations (1)
New Jersey
- Robert Wood Johnson University Hospital - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-04 |
| Est. Completion | 2013-01 |
What the finished NCT00994370 record still lists
NCT00994370 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Liver Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00994370 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00994370 about?
NCT00994370 is a clinical study titled "Measurement of Pro-angiogenic Markers in Patients With Hepatic Metastases Undergoing SIRT". This study is being done to investigate the influence of giving radiation to the liver on tumors involving the liver. Investigator is specifically looking at this effect on the blood vessels within the tumor. This effect will be measured by studying substances in the blood that the tumors produce an...
What is the current status of trial NCT00994370?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2009-04. Estimated completion is 2013-01.
What conditions does trial NCT00994370 study?
This clinical trial studies the following conditions: Liver Cancer.
Who is sponsoring clinical trial NCT00994370?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00994370 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00994370's enrollment target sits among peer trials
36 44th of 78 higher than 35 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Study of CBCT for IGRT in Cancer Patients
RECRUITING · NA
-
Collection of Blood From Patients With Cancer
RECRUITING
-
National Liver Cancer Screening Trial
RECRUITING · Phase 4
-
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
RECRUITING · NA
-
Multi-analyte Blood Test Clinical Trial
RECRUITING
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia